Literature DB >> 9588396

Assessment of platelet function assays.

N S Nicholson1, S G Panzer-Knodle, N F Haas, B B Taite, J A Szalony, J D Page, L P Feigen, D M Lansky, A K Salyers.   

Abstract

Optical aggregometry, traditionally used to assess platelet function, is highly dependent on sample preparation and technical procedure; as a result, data from various laboratories can be quite variable. In a study designed to assess the sources of variation, it was determined that the total standard deviation ranged from 3.6% to 7.7%. The assay variation by one analyst on one aggregometer on a single day ranged from 1.7 to 4.6. Day-to-day variation contributed 42% to 63% of the total variation, between-operator variation contributed 1% to 33% of the total variation, and within [between repeat measurements for a given sample by a given operator on a single day] variation contributed 22% to 36% of the total variation. Because of the disadvantages associated with optical aggregometry, alternate platelet function assays were considered and their correspondence to optical aggregometry was evaluated: activated clotting time, whole blood aggregometry, platelet count ratio, Platelet Function Analyzer (PFA-100, Dade), and Rapid Platelet function Assay (Accumetrics). Of those assays evaluated, activated clotting time and PFA-100 are assays that measure aspects of coagulation and hemostasis, whereas whole blood aggregometry, platelet count ratio, and RPFA are more closely related to platelet function. Each assay has value in monitoring various aspects of the coagulation process. The best method for monitoring safety and efficacy of various inhibitors of platelet function will ultimately be determined by clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588396     DOI: 10.1016/s0002-8703(98)70245-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

1.  Characterization of the effects of isoprostanes on platelet aggregation in human whole blood.

Authors:  J H Cranshaw; T W Evans; J A Mitchell
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  Applications of anti-platelet monitoring in catheterization laboratory.

Authors:  D Mukherjee; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

3.  The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction.

Authors:  Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron
Journal:  Transl Res       Date:  2017-12-02       Impact factor: 7.012

Review 4.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

5.  Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.

Authors:  Giulia Renda; Maria Zurro; Gelsomina Malatesta; Benedetta Ruggieri; Raffaele De Caterina
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

Review 6.  Monitoring antiplatelet therapy: What is the best method?

Authors:  D Mukherjee; D J Moliterno
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

7.  Hypoxia and Ischemia Promote a Maladaptive Platelet Phenotype.

Authors:  Scott J Cameron; Doran S Mix; Sara K Ture; Rachel A Schmidt; Amy Mohan; Daphne Pariser; Michael C Stoner; Punit Shah; Lijun Chen; Hui Zhang; David J Field; Kristina L Modjeski; Sandra Toth; Craig N Morrell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-03       Impact factor: 8.311

8.  Comparison of mean platelet volume in type 2 diabetics on insulin therapy and on oral hypoglycaemic agents.

Authors:  Pradeep V Vernekar; Kuladeepa Ananda Vaidya
Journal:  J Clin Diagn Res       Date:  2013-12-15

9.  Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.

Authors:  Jochen Graff; Ute Klinkhardt; Dagmar Westrup; Carl M Kirchmaier; Hans Klaus Breddin; Sebastian Harder
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

10.  Aspirin resistance.

Authors:  Khaled Mansour; Ali T Taher; Khaled M Musallam; Samir Alam
Journal:  Adv Hematol       Date:  2009-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.